Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
| Revenue (TTM) | $1.23B |
| Gross Profit (TTM) | $671.74M |
| EBITDA | $583.82M |
| Operating Margin | 39.80% |
| Return on Equity | 27.00% |
| Return on Assets | 8.60% |
| Revenue/Share (TTM) | $4.31 |
| Book Value | $2.57 |
| Price-to-Book | 6.18 |
| Price-to-Sales (TTM) | 3.72 |
| EV/Revenue | 5.2 |
| EV/EBITDA | 11.79 |
| Quarterly Earnings Growth (YoY) | 17.60% |
| Quarterly Revenue Growth (YoY) | 4.40% |
| Shares Outstanding | $285.63M |
| Float | $201.03M |
| % Insiders | 2.41% |
| % Institutions | 101.62% |
Volatility is currently expanding
Sotera Health NASDAQ: SHC reported third-quarter 2026 revenue growth and higher adjusted EBITDA, while reaffirming its full-year outlook despite softer demand from medical-device customers in Europe that emerged late in the quarter and continued into the start of the fourth quarter.
While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sotera Health Company (SHC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago.
Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1) , compared to Q3 2025 Q3 2026 net income of $58 million or $0.20 per diluted share Q3 2026 Adjusted EBITDA ( 1 ) increased 3.9%, or 4.0% on a constant currency basis Q3 2026 Adjusted EPS (1) of $0.29, an increase of 12% per diluted share Reaffirming full-year 2026 net revenues growth outlook of 5.25% - 6.75% and Adjusted EBITDA growth outlook of 5.75% - 7.25%, both on a constant currency basis CLEVELAND, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2026. “We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion,” said Alton Shader, Chief Executive Officer.
CLEVELAND, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. Following the release, management will host a conference call at 9:00 a.m.
Sotera Health Company is rated BUY, leveraging a vertically integrated model and strong MOAT in global medical equipment sterilization. SHC benefits from high customer switching costs, multi-year contracts with major healthcare firms, and robust pricing power in mission critical services. Q2 2026 results exceeded expectations, prompting raised full-year guidance; SHC trades at a discount to peers on forward EV/EBITDA despite superior margins.
Sotera Health NASDAQ: SHC reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook.
Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.2 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SHC and any ticker you trade — then tracks every position and per-strategy win rate.
